View this email as a web page

Genentech Ophthalmology

See How Many Patients Are Covered to Start Now

View in browser

Important Safety Information

Prescribing Information

THE ACCESS YOU NEED
FOR THE DOSING THEY NEED

~90% of patients are covered to start
VABYSMO^® (faricimab-svoa) as their first
branded treatment*

Resources are available throughout the access journey
so your patients start and stay on VABYSMO:

Our step-by-step guide discussing
coverage and reimbursement throughout
the VABYSMO treatment process

Includes information on ordering
VABYSMO to your practice

Enroll eligible commercially-insured
patients in the Genentech
Ophthalmology Co-pay Program^†

DISCOVER MORE RESOURCES

*Coverage determined for VABYSMO vial based on Medicare Fee for Service and tracking of the largest payers for other books of business. Bevacizumab (not indicated for intraocular use) and biosimilars are excluded from the branded treatment category. Specific coverage may vary for individuals and plans. Data as of January 2024.

^†Eligibility criteria apply. Not valid for patients using federal or state government programs to pay for their medicine and/or administration of their Genentech medicine. Patients must be taking the Genentech medicine for an FDA-approved indication. Please visit the Co-pay Program website for the full list of Terms and Conditions.

INDICATIONS

VABYSMO (faricimab-svoa) is a vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), and Macular Edema following Retinal Vein Occlusion (RVO).

IMPORTANT SAFETY INFORMATION

Contraindications

VABYSMO is contraindicated in patients with ocular or periocular infection, in patients with active intraocular inflammation, and in patients with known hypersensitivity to faricimab or any of the excipients in VABYSMO.

Warnings and Precautions

•

Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit prompt and appropriate management.

•

Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection.

•

There is a potential risk of arterial thromboembolic events (ATEs) associated with VEGF inhibition.

•

Retinal vasculitis and/or retinal vascular occlusion have been reported. Patients should be instructed to report any change in vision without delay.

Adverse Reactions

The most common adverse reactions (≥5%) reported in patients receiving VABYSMO were cataract (15%) and conjunctival hemorrhage (8%).

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see additional Important Safety Information in the full VABYSMO Prescribing Information.

For Colorado Prescribers: In accordance with Colorado Law, please access Wholesale Acquisition Cost (WAC) pricing information here.

This content is sponsored by Genentech, and Specialty Practice Network has not independently reviewed or verified the information provided by Genentech.

This email was sent to meghan.jacobson@cencora.com because you have an account with or are a valued partner of Cencora Specialty GPOs | ION Oncology Practice Network. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.